Dietary Magnesium in Preventing Low Blood Magnesium Levels in Patients With Ovarian Cancer Receiving Carboplatin Chemotherapy
Feasibility of Dietary Magnesium Replacement for Prevention of Hypomagnesemia in Ovarian Cancer Patients Receiving Carboplatin Chemotherapy
Sponsor: M.D. Anderson Cancer Center
This NA trial investigates Ovarian Carcinoma and is currently ongoing. M.D. Anderson Cancer Center leads this study, which shows 12 recorded versions since 2019 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
12 versions recorded-
Feb 2026 — Present [monthly]
Active Not Recruiting NA
-
Sep 2025 — Feb 2026 [monthly]
Active Not Recruiting NA
-
Mar 2025 — Sep 2025 [monthly]
Active Not Recruiting NA
-
Nov 2024 — Mar 2025 [monthly]
Active Not Recruiting NA
-
Sep 2024 — Nov 2024 [monthly]
Active Not Recruiting NA
▶ Show 7 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting NA
-
Mar 2024 — Jul 2024 [monthly]
Active Not Recruiting NA
-
Sep 2023 — Mar 2024 [monthly]
Active Not Recruiting NA
-
Jul 2022 — Sep 2023 [monthly]
Active Not Recruiting NA
Status: Unknown Status → Active Not Recruiting
-
Apr 2022 — Jul 2022 [monthly]
Unknown Status NA
Status: Recruiting → Unknown Status
-
Jan 2021 — Apr 2022 [monthly]
Recruiting NA
-
Apr 2020 — Jan 2021 [monthly]
Recruiting NA
First recorded
Apr 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- M.D. Anderson Cancer Center
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .